Merus (MRUS) Raised to “Hold” at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Merus (NASDAQ:MRUS) from a sell rating to a hold rating in a research note issued to investors on Saturday, BidAskClub reports.

Several other equities analysts also recently weighed in on the company. Royal Bank of Canada upgraded Merus from a sector perform rating to an outperform rating and increased their target price for the stock from $18.00 to $23.00 in a research report on Wednesday, April 3rd. ValuEngine downgraded Merus from a hold rating to a sell rating in a research report on Monday, February 4th. Berenberg Bank initiated coverage on Merus in a research report on Wednesday, March 27th. They set a buy rating and a $35.00 target price on the stock. Citigroup reduced their target price on Merus from $18.00 to $16.00 and set a neutral rating on the stock in a research report on Thursday, March 21st. Finally, Guggenheim initiated coverage on Merus in a research report on Friday. They set a buy rating and a $25.00 target price on the stock. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $23.00.

NASDAQ MRUS opened at $16.45 on Friday. Merus has a twelve month low of $11.00 and a twelve month high of $26.74. The stock has a market cap of $349.21 million, a P/E ratio of -8.94 and a beta of -0.06.

A number of large investors have recently made changes to their positions in MRUS. Squarepoint Ops LLC increased its stake in Merus by 10.3% during the fourth quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 1,100 shares during the last quarter. Geode Capital Management LLC increased its stake in Merus by 18.8% during the fourth quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 2,373 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Merus by 33.8% during the third quarter. JPMorgan Chase & Co. now owns 17,723 shares of the biotechnology company’s stock worth $350,000 after acquiring an additional 4,476 shares during the last quarter. Morgan Stanley increased its stake in Merus by 74.3% during the third quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock worth $1,415,000 after acquiring an additional 30,538 shares during the last quarter. Finally, Artal Group S.A. acquired a new stake in Merus during the fourth quarter worth about $2,886,000. Institutional investors own 53.06% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

See Also: What is the Difference Between Common Shares and Convertible Shares?

Analyst Recommendations for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Q2 2019 Earnings Forecast for Coeur Mining Inc  Issued By Cormark
Q2 2019 Earnings Forecast for Coeur Mining Inc Issued By Cormark
Alliance Data Systems Co.  Forecasted to Post Q3 2019 Earnings of $5.50 Per Share
Alliance Data Systems Co. Forecasted to Post Q3 2019 Earnings of $5.50 Per Share
Q3 2019 EPS Estimates for Fortinet Inc  Lowered by Oppenheimer
Q3 2019 EPS Estimates for Fortinet Inc Lowered by Oppenheimer
GTX  and Maxar Technologies  Head to Head Comparison
GTX and Maxar Technologies Head to Head Comparison
Head to Head Contrast: CenterPoint Energy  vs. Clearway Energy
Head to Head Contrast: CenterPoint Energy vs. Clearway Energy
Greggs plc  Given Consensus Rating of “Hold” by Brokerages
Greggs plc Given Consensus Rating of “Hold” by Brokerages


 
© 2006-2019 Zolmax.